Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Plasma lipidome is dysregulated in Alzheimer’s disease and is associated with disease risk genes

Abstract

Lipidomics research could provide insights of pathobiological mechanisms in Alzheimer’s disease. This study explores a battery of plasma lipids that can differentiate Alzheimer’s disease (AD) patients from healthy controls and determines whether lipid profiles correlate with genetic risk for AD. AD plasma samples were collected from the Sydney Memory and Ageing Study (MAS) Sydney, Australia (aged range 75–97 years; 51.2% male). Untargeted lipidomics analysis was performed by liquid chromatography coupled–mass spectrometry (LC–MS/MS). We found that several lipid species from nine lipid classes, particularly sphingomyelins (SMs), cholesterol esters (ChEs), phosphatidylcholines (PCs), phosphatidylethanolamines (PIs), phosphatidylinositols (PIs), and triglycerides (TGs) are dysregulated in AD patients and may help discriminate them from healthy controls. However, when the lipid species were grouped together into lipid subgroups, only the DG group was significantly higher in AD. ChEs, SMs, and TGs resulted in good classification accuracy using the Glmnet algorithm (elastic net penalization for the generalized linear model [glm]) with more than 80% AUC. In general, group lipids and the lipid subclasses LPC and PE had less classification accuracy compared to the other subclasses. We also found significant increases in SMs, PIs, and the LPE/PE ratio in human U251 astroglioma cell lines exposed to pathophysiological concentrations of oligomeric Aβ42. This suggests that oligomeric Aβ42 plays a contributory, if not causal role, in mediating changes in lipid profiles in AD that can be detected in the periphery. In addition, we evaluated the association of plasma lipid profiles with AD-related single nucleotide polymorphisms (SNPs) and polygenic risk scores (PRS) of AD. We found that FERMT2 and MS4A6A showed a significantly differential association with lipids in all lipid classes across disease and control groups. ABCA7 had a differential association with more than half of the DG lipids (52.63%) and PI lipids (57.14%), respectively. Additionally, 43.4% of lipids in the SM class were differentially associated with CLU. More than 30% of lipids in ChE, PE, and TG classes had differential associations with separate genes (ChE-PICALM, SLC24A4, and SORL1; PE-CLU and CR1; TG-BINI) between AD and control group. These data may provide renewed insights into the pathobiology of AD and the feasibility of identifying individuals with greater AD risk.

Introduction

Alzheimer’s disease (AD) is the most common cause of dementia, accounting for about 70% of total cases1. This progressively neurodegenerative disease is characterized by an insidious onset and is clinically defined by a progressive loss of memory and other cognitive deficits. AD has become one of the major challenges for the public health and economic system of the 21st century. There is still no international consensus on the etiology of this multifactorial disease, in which in addition to proteinopathies, oxidative stress, inflammation, metabolic disorder, and other factors play a part2,3,4.

The lack of effective treatments and the potential for prevention highlight the importance of identifying early biomarkers for diagnosing AD. In addition, there is evidence that pathological processes associated with AD can also manifest in the peripheral system5, indicating the possibility of identifying non-invasive blood biomarkers. Lipids participate in important functions such as cell membrane formation, cellular transport, and energy storage, and act as essential signaling molecules. Beyond their structural roles, lipids have also been shown to act as modulators of transmembrane proteins, such as ion channels, whereby alteration of the composition or conformation of lipids surrounding ion channels can affect their function6,7. Given the essential role of lipids in major biological processes, blood lipids have emerged as promising biomarkers for AD8,9,10.

Although there have been many studies on the association between lipids and the pathobiology of AD, there are few studies on the plasma lipidome in AD. In contrast to classical biochemical approaches that focus on single metabolites or reactions, lipidomics approaches simultaneously identify and quantify hundreds of lipids. Measurement of large numbers of lipids enables network analysis approaches and provides means to identify critical metabolic drivers in disease pathophysiology. Lipidomics provides powerful tools for mapping global biochemical changes in disease and treatment.

In our current study, we examined differences in the plasma lipidome between AD and ‘healthy’ age-matched controls and compared the ability of different lipid profiles to discriminate between the two groups. We also showed that human astroglioma cultures exposed to pathological levels of amyloid-beta (Aβ)42 oligomers shared similar cellular lipidomic profiles to those observed in human plasma AD. We explored the effect of AD polygenic risk scores and AD-related SNPs on plasma lipid levels between AD and controls.

Method

Participants

Participants were a subsample from the population-based longitudinal Sydney Memory and Ageing Study (Sydney MAS)11, an ongoing study that began in 2005 and focuses on cognitive decline in community-dwelling elderly. Participants were aged 70–90 years, initially without dementia, living in the community, and able to complete their assessments in English. There have been four Waves of data collection, two years apart. At each Wave, participants underwent an MRI scan, comprehensive neuropsychological assessment, medical examination, and blood collection for biochemistry analyses and DNA extraction. Written informed consent was obtained from all participants. In this study, AD (diagnosed by NINCDS-ADRDA criteria) and cognitively normal control samples were collected at Waves 2 and 4. Ethics approval for this study was obtained from UNSW Sydney Australia and the South-Eastern Illawarra Area Health Service—Eastern sector11. The investigators were blinded to sample allocation during the study and outcome assessment.

Plasma lipid extraction

Plasma lipids were extracted as previously described12. Briefly, 10 µL internal lipid standards (ISTDs) (Avanti lipids, https://avantilipids.com/product/330707) were added to 10 µL aliquot of each plasma sample. 100 µL of 1-butanol-Methanol (1:1 v/v) containing 5 mM ammonium formate were used to dissolve the mixture. Samples were vortexed for 10 s then sonicated for one hour. Afterward, samples were centrifuged at 13,000 × g for 10 min. The supernatant was transferred into a fresh Eppendorf tube. A further 100 µL of 1-butanol/methanol (1:1 v/v) with 5 mM ammonium formate was added to the white pellet to re-extract any remaining lipids. The supernatant was dried in a speed vacuum centrifuge for 40–60 min. The lipids were reconstituted by adding 100 µL of 1-butanol/methanol (1:1 v/v) containing 5 mM ammonium formate to each tube. The contents were transferred into a 300 µL glass Chromacol vial with a glass insert prior to liquid chromatography/mass spectrometry (LC–MS).

Liquid chromatography/mass spectrometry

Lipid analysis was performed by LC ESI-MS/MS using a Thermo QExactive Plus Orbitrap mass spectrometer as previously described12. Briefly, a Waters ACQUITY UPLC CSHTM C18 1.7 μm, 2.1 × 100 mm column was used for liquid chromatography at a flow rate of 260 gl/min, using the following gradient condition: 32% solvent B to 100% over 25 min, a return to 32% B and finally 32% B for 5 min prior to the next injection. Solvents A and B consisted of acetonitrile: MilliQ water (6:4 v/v) and isopropanol:acetonitrile (9:I v/v) respectively, both containing 10 mM ammonium formate and 0.1% formic acid. The first 3 min of eluent, containing the eluted salts, was diverted to waste. A product ion scan in positive and negative ion modes was performed to analyze the individual lipid species. The order of sampling was randomized prior to analysis. Ceramide (Cer), sphingomyelin (SM), phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylinositol (PI), lyso-phosphatidylcholines (LPC), cholesterol esters (ChE), diacylglycerol (DG) and triacylglycerols (TG) were detected. The abundance of lipids was acquired using Lipidsearch software version 4.2 (Thermo Fisher Scientific, Sydney, NSW AU) according to accurate lipid mass and fragment matching12. The LC–MS data were exported into Microsoft Excel and normalized by dividing the abundance of internal standards to be used for further statistical analyses.

Cell lipidomics

Cell culture

U251 human astroglioma cell lines were purchased from the ATCC. These cells were cultivated in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented with 10% fetal bovine serum, 1% 1-glutamax, and 1% antibacterial/antifungal. The cells were recently tested and found to be mycoplasma-free using the MycoAlert Mycoplasma Detection Kit (Lonza). The cells were grown at 37 °C in 95% humidified air and 5% CO2. The culture medium was replaced every 2 days. U251 cells were seeded in a 12-well microtitre plate and given treatment when cells were nearly at confluency (0.5 × 106 cells per well). Groups for evaluation are as follows: 6 wells containing naive U251 cells with no treatment (control) for 24 h, and 6 wells containing U251 cells treated for 24 h with 5 µM oligomeric Aβ42 (see below for further details).

Preparation of recombinant Aβ42 peptide

42 peptide was purchased from Recombinant Peptide Technologies (Athens, GA, USA). The peptide was immediately stored in sealed glass vials at −80 °C in a lyophilized form. Consistent homogenous preparations of recombinant Aβ42 oligomers or fibrils for use in cell culture stimulation experiments were obtained following a previously published protocol13. To avoid condensation upon opening, each vial was left at room temperature for 30 min prior to resuspension. Using 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma, Castle Hill, Australia), the lyophilized peptide was initially dissolved to 1 mM and separated into 50 μl aliquots in sterile microcentrifuge tubes. Aliquots were left for 3 h in a fume hood, which allowed almost complete evaporation of HFIP. The resulting peptide films were further dried under vacuum using a Speed Vac (ThermoSavant, Patterson, CA, USA). This procedure is important as HFIP evaporated Aβ will form fibrils if exposed to moisture in the air, hence it is paramount to store HFIP evaporated Aβ films in desiccant. These preparations were then stored at −20 °C until required.

Production of recombinant Aβ42 oligomers

Each HFIP aliquot of the peptide film was thoroughly resuspended to 5 mM in anhydrous dimethyl sulfoxide (DMSO; Sigma, Castle Hill, Australia) via pipette mixing, followed by 10-min bath sonication (Model: FX8, Unisonics, Sydney, Australia). Oligomers were formed by adding ice-cold Dulbecco’s modified Eagle medium/Ham F-12 without phenol red (Sigma, Castle Hill, Australia) to a final concentration of 100 μM. Following a 30 s vortex, the preparation was incubated at 4 °C for 6 weeks for the formation of Aβ42 oligomers.

Cell lipidomics

Samples were collected using a cell scraper to 1 mL PBS solvent. After centrifuging 5 min at 13,000 × g, cell pellets were collected and reconstituted in 110 µL MilliQ water. 10 µL of cell solution was used for protein assay and the rest was used for lipid extraction. Lipids extraction and LC–MS methods were the same as plasma lipids, which were described above. 10 lipid classes including Cer, SM, PC, PE, PI, LPC, lyso-phosphatidylethanolamines (LPE), ChE, DG, and TG were detected.

Quantification of oligomeric Aβ

Oligomeric Aβ was quantified as previously described14. Briefly, plasma samples were thawed at 37 °C for 15 min. Afterwards, 10 μl of plasma, 4 μl of HAMA (human anti-murine antibody, HAMA) blocker (Scantibodies Laboratory, Santee, CA, USA), were mixed. 10 μl of PBR-1 (1% proprietary + 1.25% dimethyl sulfoxide (DMSO) + 96.75% phosphate-buffered saline contains Tween 20 (PBST) + 1% ultra-pure water) were further mixed into the plasma mixture. The mixtures were incubated for 48 and 1 h, respectively. The plasma sample mixture and serially diluted standards were added to separate wells of the plate in a total volume of 100 μl. The plates were incubated at RT for 1 h. The detection antibody was added to the wells, and the plate was incubated for 1 h at RT. Finally, 100 μl of 3,3′,5,5′-tetramethylbenzidine (TMB) reagent was added as a substrate, and after 15 min, the reaction was stopped with 50 μl of 1 M H2SO4. Optical density (OD) values were measured using the BMG Fluostar Optima multimode plate reader (NY, USA), at a wavelength of 450 nm. Prior studies using this method detected the raw luminescence signal and used relative luminescence units (RLU) to present the oligomeric Aβ levels15.

Genotyping

DNA was extracted using standard procedures. Genotyping of the APOE ε2/3/4 polymorphism was performed as described16. Genome-wide genotyping was undertaken using the Affymetrix Genome-wide Human SNP Array 6.0 (California, USA) at the Ramaciotti Centre, UNSW Australia17. The CRLMM package (v1.10.0) in R (v2.12.1) was used to call genotypes. SNPs were excluded if the genotyping call rate was <95%, had a minor allele frequency <0.01 or if they failed a Hardy–Weinberg equilibrium threshold of <1 × 10−6. After further QC checks, there were 925 Sydney MAS participants with data for 734,550 SNPs. Imputation was undertaken to the 1000 Genome reference panel using the Michigan Imputation Server. SNPs with poor imputation quality were omitted from any further analyses (R2 ≤ 0.6).

Polygenic Risk Scores (PRS) and AD implicated SNPs

PRS were generated using the PRSice program18 from summary statistics obtained from a previous Alzheimer’s disease GWAS19. Linkage disequilibrium pruning was performed using the clumping option (r2 > 0.25 and physical distance threshold of 250 kb KB). We present the association of lipids with the PRS calculated using the SNPs with the AD GWAS p-value threshold ≤5 × 10−5. Associations between 33 individual AD-related SNPs20 that passed QC checks (SNPs with MAF > 0.05 and imputation quality >0.6) and lipids were also undertaken. Details regarding the SNPs and their associated genes utilized in the analyses are provided in Supplementary Table 1.

Statistical methods

Comparison of lipids between AD and controls

Inverse normal transformed residuals for the individual lipids and group lipids were obtained after regressing out the effect of possible confounders: age, sex, BMI, diabetes status, hypertension status, medication status for hypertension and hyperlipidemia, APOE e4 carrier status, education, and current smoking status. This transformed data was used in all subsequent analyses. T-tests were used to compare the mean value of lipids residuals between AD and controls. We used a significance threshold of 0.05 after False discovery rate (FDR) correction for all comparisons. Fold change (FC) was calculated as the ratio of the average lipids abundance in AD and controls. T-tests were also applied to compare lipid abundance between Aβ treated and untreated cells. Between-group comparisons are done assuming unequal variance between groups with an approximation for degrees of freedom.

Classification of AD vs. Control using GLMnet

We used a machine-learning algorithm, glmnet (elastic net penalization for the generalized linear model [glm]) to classify AD versus control samples. A combination of two penalty functions with two tuning parameters was utilized to shrink the beta coefficients in the glm21. R (version 3.5.1)22 package caret23 for fitting the elastic net glm model with default options was used to identify the optimum values for the tuning parameters.

For classification analysis, the data were randomly split into 70% training and 30% test samples maintaining the proportion of cases and controls in the training and test samples as in the full dataset. For the training data, the algorithms were run with three cross-validations with five repeats. To avoid bias due to a single random split of the original data, we have repeated the analysis 10 times and the results were summarized over the 10 iterations.

The glmnet classification accuracy was examined based on several subgroups of the lipid species. The receiver operating curve (ROC) and area under ROC (AUC) were obtained using the R package pROC24. Average sensitivity (proportion of AD cases predicted by the model in the test data), specificity (proportion of controls predicted by the model in the test data), and the AUC across 10 iterations are reported.

Genetic variation and lipid profiles among AD vs. controls

Linear regression was used to examine the association of AD risk variants and AD PRS with the lipids. The inverse normal transformed lipid residuals were used as the dependent variable and individual SNPs or PRS, case-controls (CC) status (AD vs. controls), and the relevant interaction term (CC × SNP or CC × PRS) were used as independent variables. Differential association of the AD risk variants and the PRS with lipids among cases and controls were examined based on the significance of the interaction term.

Results

Descriptive statistics

The sample comprised 82 plasma samples (40 AD patients and 42 cognitively normal ‘healthy’ controls) from the Sydney MAS cohort. The demographic information of participants is displayed in Table 1. The AD patients were significantly older than the controls with all aged more than 75 years old. There were no gender differences between the 2 groups (χ2 = 1.233, p = 0.267). As expected, cognitive scores on the Mini-Mental State Examination (MMSE) were significantly lower in AD patients. Education levels, which represent a protective factor for AD were measured in years and showed no statistical difference between the AD and control groups. AD and controls did not differ in vascular risk factors, including frequency of hypertension, diabetes, and current smoking status. Carriers of the APOE*4 allele, a strong genetic risk factor for AD risk, were more common in AD patients than controls, although this did not reach statistical significance (AD 37.5% vs. control 19%, χ2 = 3.457, p = 0.063). The elevated levels of oligomeric Aβ in the plasma distinguished the AD and control groups and were associated with increased MMSE, in patients with AD.

Table 1 Characteristics of Alzheimer’s disease and control participants.

Comparison of lipids between AD and control patients

A total of 778 distinct lipid species from 9 lipid classes were analyzed, including neutral lipids such as 14 cholesteryl esters (ChE), 50 diglycerides (DG), 382 triglycerides (TG); sphingolipids including 43 ceramides (Cer), 90 sphingomyelins (SM); and phospholipid subclasses including 120 phosphatidylcholines (PC), 24 lyso-phosphatidylcholines(LPC), 38 phosphatidylethanolamines (PE), and 17 phosphatidylinositols (PI). The proportion of lipids significantly different between AD and controls according to each of the examined lipid classes are shown in Fig. 1. Volcano plots were drawn according to lipid fold changes of abundance comparing AD and controls and FDR-corrected p values in for all individual lipid species (see Fig. 2 and Supplementary Table 2).

Fig. 1: Proportion of lipids significantly different between AD and control in lipid classes.
figure 1

Overall pie chart presenting the number of lipids measured in each lipid class. Separate pie charts describing the proportion of lipids with non-significant differences or significantly higher/lower in AD versus controls for each lipid class. Cer ceramides, SM sphingomyelins, ChE cholesteryl esters, DG diglycerides, TG triglycerides, PC phosphatidylcholines, LPC lyso-phosphatidylcholines, PE phosphatidylethanolamines, PI phosphatidylinositols.

Fig. 2: Volcano plots showing significant lipid species in the nine separate lipid groups.
figure 2

Each dot on the plot is a single lipid species. Horizontal axis: fold change (in log2 scale); vertical axis: adjusted p-value (in log10 scale). Vertical dashed lines highlight log2 fold changes of −1 and +1, while a horizontal dashed line represents a p-value of 0.05. Cer ceramides, SM sphingomyelins, ChE Cholesteryl esters, DG diglycerides, TG triglycerides, PC phosphatidylcholines, LPC lyso- phosphatidylcholines, PE phosphatidylethanolamines, PI phosphatidylinositols.

Almost all ceramides were significantly different between control and AD groups after adjustment for age, sex, and vascular risk factors, even after multiple testing corrections. Molecular profiles of the ceramidome showed that dihydroxy Cer species comprising fatty acyls (18C) with 0 or 2 double bonds and all dihydroxy Cer with 19C were significantly higher in AD. On the other hand, dihydroxy Cer containing 16C or 18C with 1 double bond showed the opposite results. Most monohydroxy and trihydroxy Cer were significantly lower in AD subjects. Four AD positive ceramides including Cer(d18:0_16:0), Cer(d19:1_24:0), Cer(d18:0_23:0), and Cer(d18:2_25:0), and AD negatively correlated ceramides: Cer(d18:1_23:0), Cer(t16:1_14:0), Cer(m18:1_20:0), Cer(m18:0_22:0), and Cer(d19:1_22:0) showed the largest fold changes (FC > 4). Sphingomyelin is another type of sphingolipid. Most lipids in SM class showed significantly lower levels in AD plasma. The lipids with FC > 4 included SM(d35:4), SM(d34:1), SM(d31:1), SM(d18:1_21:0), SM(t36:2), and SM(d40:4). In contrast, SM(d41:1), SM(d41:4), and SM(d18:1_24:3) were largest downregulated in AD.

In the AD cases, there was a higher abundance of PC lipids compared to controls. They were comprised of very short and short-chain fatty acyls except for PC containing C15 without double bonds and C16 with 2 double bonds. The largest fold changes were observed in PC(16:0_22:6), PC(18:2_18:2), PC(18:0_20:4), PC(36:2), PC(16:1_22:5) that showed upregulation in AD. PC (20:2_18:2) and PC (38:7) showed lower plasma concentrations in AD. LPCs with longer fatty acid chains tended to be lower in AD patients. No LPC lipids differed significantly between cognitively normal and AD groups. Most of PE lipids were lower in AD-affected patients. Major PE lipids were reduced in AD, including highly changed (FC > 4) PE (16:0p_22:6), PE(18:0p_20:4), PE(16:0p_18:1), and PE(18:0p_22:4). PE (18:0_18:1) was higher in plasma of Alzheimer’s patients. PI showed an elevated abundance in AD and the PI lipids, with PI (18:0_18:3) and PI (18:1_20:4) the most significantly elevated in AD cases.

ChE (18:3), ChE (20:3), and ChE (22:3) showed the largest fold changes. Consistent with the result of group DGs, most DG lipids species were higher in AD patients, including DG(16:0_18:3), DG(22:4e), DG(17:1_18:1), DG(20:0_18:2), and DG(36:4e) with largest fold changes. Most downregulated DGs include DG(18:1_20:4), DG(16:0_18:1), and DG(18:0_18:1).

As well, around 30% of TG lipids were observed to be higher in AD patients. The most upregulated TG lipids include TG(18:1_17:1_18:3), TG(14:0_18:2_20:5), TG(16:1_20:1_22:4), TG(60:10), and TG(18:1_18:1_22:5). On the other hand, most of the long-chain polyunsaturated fatty acid-containing TGs were reduced in AD compared to age-matched controls. About 18% of plasma TG lipids are decreased in AD patients, and TG(18:1_12:0_14:0), TG(18:4_16:1_18:3), TG(16:0_20:4_22:6), TG(16:0_14:0_18:1), and TG(16:0_16:0_16:0) showed the largest fold changes. We also identified suggestive group differences between almost all species containing more than 2 double bonds. Nine lipid groups calculated by summarizing all lipid species in the same lipid class were compared between AD and controls (Fig. 3 and Supplementary Table 3). Only the DG group was significantly higher in AD (p = 0.009, mean of residuals: Control: −0.276 ± 0.143, AD:0.290 ± 0.154). Other lipid group’s lipids did not differ after adjusting for covariates.

Fig. 3: Residuals of group lipids in AD and control group.
figure 3

Cer ceramides, SM sphingomyelins, ChE cholesteryl esters, DG diglycerides, TG triglycerides, PC phosphatidylcholines, LPC lyso-phosphatidylcholines, PE phosphatidylethanolamines, PI phosphatidylinositols. Dots in the plot represent the residuals of group lipids in each participant. Residuals were obtained after regression out age, sex, BMI, diabetes status, hypertension status, medication status for hypertension, and hyperlipidemia, APOE e4 carrier status, education, and current smoking status. T-tests were used to compare the lipid differences between AD and controls. ns: no significance, *p < 0.05.

Cell lipidomics

Results are plotted in Fig. 4. The concentration of oligomeric peptide used in this study is similar to that reported from human CSF and human cell culture conditioned medium25,26. Additionally, it also represents a concentration closer to the levels found in brain25,26 offering a more physiologic impression of the effect of Aβ oligomers on astrocyte glial lipid profiles. SMs were significantly elevated in astroglioma cells treated with Aβ42 oligomers compared to non-treated cells (p = 0.0015). No significant differences were found in phospholipids except that the level of the PI group was higher in the Aβ42 group (p = 0.041), which is consistent with the result found in human AD plasma samples. Even though PE and LPE were not significantly different between treated and non-treated cells, the ratio of LPE/PE significantly increased in Aβ42-treated astrogliomas (p value). TG was also increased in the Aβ42 group (p = 0.005).

Fig. 4: Normalized lipid group abundance in amyloid beta-treated astrocytes versus controls.
figure 4

Cer ceramides, SM sphingomyelins, ChE Cholesteryl esters, DG diglycerides, TG triglycerides, PC phosphatidylcholines, LPC lyso-phosphatidylcholines, PE phosphatidylethanolamines, PI phosphatidylinositols. T tests were used to compare lipids between two groups. ns: no significance, *p < 0.05, **p < 0.01.

Classification of AD vs. Control using lipid profiles

Several models were used for the classification of AD versus controls based on the plasma lipidome profile. The glmnet package was used in all the analyses. The analyses were repeated 10 times and results were summarized across the 10 iterations. The algorithms were run in turn using the full list of individual lipids, all of the 9 subclasses of lipids, and group lipids. The average sensitivity, specificity, and AUC of the test data are summarized in Table 2. The ROC curves for the top 3 models, ChE, SM, and TG are presented in Fig. 5 and resulted in good classification accuracy with more than 80% AUC. In general, group lipids and the lipid subclasses LPC and PE had less classification accuracy compared to the other subclasses.

Table 2 GLMnet results of lipid models in the classification of AD versus control.
Fig. 5: ROC of TG, ChE, and SM lipid models in the classification of AD versus control by GLMnet.
figure 5

SM sphingomyelins, ChE cholesteryl esters, TG triglycerides, GLMnet elastic net penalization for the generalized linear model.

SNPs and lipids with AD versus control

The associations of AD PRS and AD-related SNPs with the lipidome were examined. The individual lipids that were significantly different between AD and controls (n = 420) were utilized to explore the association. No significant association of AD PRS with lipids was observed after FDR correction (Supplementary Table 4). However, the AD PRS × CC interaction was nominally significant (p-value < =0.05) for 57 lipid species (Table 3), which were mainly PCs, SMs, and TGs. Out of the 57 significant interactions, only two PRS scores had marginal significant effects (p value < 0.05). The same analysis was also repeated using 33 AD implicated individual SNPs recently identified in another study20. All of these individual SNPs were found to have different effects on a certain number of lipids between AD and controls before adjustment for multiple testing. Nominally significantly different associations of SNPs with lipids between AD and controls are listed in Supplementary Table 5.

Table 3 Nominally significantly differential association of the AD risk PRS with lipids between AD and controls control.

We further explored the association of AD-associated genes (n = 19) derived from the list of 33 SNPs with lipids in each lipid class (Table 4). FERMT2 and MS4A6A showed a significantly differential association with lipids in all lipid classes across disease and control groups. In addition, PC, SM, and TG lipids were differentially associated with the largest number of AD-related genes. The heatmap in Fig. 6 shows the proportion of lipids in each lipid class having differential associations with the AD-associated genes. ABCA7 had a differential association with more than half of the DG lipids (52.63%) and PI lipids (57.14%), respectively. Additionally, 43.4% of lipids in the SM class were differentially associated with CLU. More than 30% of lipids in ChE, PE, and TG classes had differential associations with separate genes (ChE-PICALM, SLC24A4, and SORL1; PE-CLU and CR1; TG-BINI) between AD and control group. Finally, we found 43 lipids that were significantly associated with both the AD-related genes and PRS (Table 5).

Table 4 Differential interaction of genes with lipids between AD and control.
Fig. 6: Proportion of lipids significantly differentially associated with AD-related genes.
figure 6

ABCA7 ATP binding cassette subfamily A member 7, BIN1 bridging integrator 1, CASS4 Crk associated substrate 4, CD2AP CD2 associated protein, CD33 sialic acid binding Ig-like lectin 3, CUGBP elav-like family member 1, CLU clusterin, CR1 complement C3b/C4b receptor 1, EPHA1 EPH receptor A1, FERMT2 FERM domain containing kindlin 2, INPP5D inositol polyphosphate-5-phosphatase D, MEF2C myocyte enhancer factor 2C, MS4A6A membrane spanning 4-domains A6A, NME8 NME/NM23 family member 8, PICALM phosphatidylinositol binding clathrin assembly protein, PTK2B protein tyrosine kinase 2 beta, SLC24A4 solute carrier family 24 member 4, SORL1 sortilin related receptor 1, ZCWPW1 zinc finger CW-type and PWWP domain containing 1.

Table 5 Overlap of lipids with significant association with SNPs and PRS scores.

Discussion

In this study, significant differences in plasma lipids between AD cases and controls were observed. In vitro analyses demonstrated similar changes in astroglial cells when treated with 42. GLMnet algorithm was used to distinguish AD from controls using different plasma lipid-based models. SMs, ChEs, and TGs showed the greatest accuracy in discriminant analysis with AUC of more than 80%. Finally, associations between AD case-control status and genetic risk factors for AD were nominally significant when examining lipid profiles.

Identification of the roles of lipids associated with AD

Our study did not show a significant group ceramide difference between AD and controls. However, we found that most individual ceramides differed significantly between these two groups. Molecular profiles of the ceramidome showed that dihydroxy Cer species, comprising fatty acyls (18C) with 0 or 2 double bonds and all dihydroxy Cers with 19C, were significantly increased in AD. On the other side, dihydroxy Cers containing 16C or 18C with 1 double bond showed an opposite result. Most monohydroxy and trihydroxy Cers decreased significantly in AD subjects, which might suggest the opposite pathobiology of different Cer subgroups. Ceramides are essential for the maintenance of membrane structure stabilization, cell-to-cell recognition, and secondary messenger signaling27. Dysregulation of Cers has been linked to cognitive decline and brain atrophy28. Higher levels of serum ceramide were associated with increased risk of AD compared to subjects with the lowest tertile of serum ceramide levels in another study29. In addition, even though the sum of SM lipids was not significantly different between the two groups, we found that most individual SM lipids were lower in AD plasma. Altered sphingolipid metabolism has been associated with the pathogenesis of several neurodegenerative diseases including AD, and metabolic syndrome29,30,31,32. The decrease in SM lipids has been shown to be strongly correlated with parameters of insulin resistance, and lipid metabolism, which are major risk factors for AD33. A cross-sectional study (n = 26 NC, 26 AD) observed reduced SM species in AD versus controls and long aliphatic chains (C22, C24) in particular 31, which is consistent with our results.

We did not find any significant differences among group PC lipids. However, the AD population tended to present higher abundance in individual PC lipids comprising very short and short-chain fatty acyls except for PC containing C15 without double bonds and C16 with 2 double bonds. Recent studies have demonstrated altered PC metabolism in cognitively impaired elderly and AD patients9,34,35. Similar to PC lipids, we did not observe significant changes in group PE. About 24% of individual PEs were all lower in AD patients, which is almost 2 fold of PEs that were higher in AD. PE has been previously reported to be significantly reduced in the brains of individuals with AD and HD36. Since a multitude of neuropathological processes can lead to a decrease in PC and PE, it is likely that reduced levels of these phospholipids may be linked to the observed neuronal loss. Increased activities of the Kennedy pathway enzymes, phosphoethanolamine cytidylyltransferase, phosphocholine cytidylyltransferase, and PS synthase have been previously reported to be elevated in the diseased brain regions of patients with AD and PD34. Contrary to the decreased trend of other phospholipids, including PC and PE, we observed an opposite change in PI in AD patients, with most of the individual PI lipids higher in AD subjects. PI is another phospholipid that is present in the membrane of almost all cell types and is involved in mediating Ca2+ mobilization in response to many hormones, neurotransmitters, and growth factors37. Consistently, an animal study showed that lower levels of plasma PC and higher plasma PI were correlated with post-stroke cognitive impairment38.

We also found significant differences in ChEs between AD and controls. ChE is produced in the plasma by the conversion of fatty acids to cholesterol from PC by the enzymatic activity of cholesterol acyl transferase (LCAT)9,39. While free cholesterol can be taken up by APOE containing liposomes (e.g. HDL) and is bound to the outer particle surface, esterification enhances cholesterol uptake within the interior of the lipoproteins and enhances cholesterol transport through the bloodstream. LCAT has a preference for highly unsaturated fatty acid chain PC and can link the reduction in PC to dysregulation of specific steps in cholesterol metabolism in AD40. Another enzyme, acyl-coenzyme A can also esterify cholesterol in other tissues. Inhibition of this enzyme has been reported to reduce amyloid plaque load in the brain of AD mice and improves cognitive outcomes41. Consistent with our results showing a significant increase of DGs in Alzheimer’s disease, previous studies have demonstrated augmented levels of DGs in the frontal cortex and plasma of AD patients42. DGs are important in maintaining structural integrity and signal transduction42 The conversion of DGs to phosphatidic acid by DG kinase has been reported to be decreased in the AD brain43. We also found almost 2/3 plasma TG lipids in all significant TG lipids were higher in AD subjects, even though the abundance of group TGs were not different among disease groups. A longitudinal finding was reported in the Honolulu-Asia Aging Study in which a 1SD increase in TG levels during midlife significantly increased the risk of dementia a quarter of a decade later44. The exploration of the exact pathobiology of individual TG lipids is needed in the future.

Relationship between plasma lipid profiles and the cell lipidome exposed to oligomeric Aβ42 in vivo

Several studies have reported significant differences in lipid profiles between plasma and postmortem brain tissue45. The separation of the brain from the periphery is a major challenge when examining the biological significance of plasma lipids in Alzheimer’s disease since not all lipids can be transported across the blood–brain barrier. This separation may likely be compromised by age-related changes in blood–brain barrier integrity, affecting lipid and Aβ kinetics. To determine whether our observed changes in the plasma lipidome were related to AD pathology we also quantified the cellular lipidome in human U251 astroglioma cell lines exposed to pathophysiological concentrations of oligomeric Aβ42.

Astrocytes are important cells in the CNS and are involved in various physiological aspects46. Neurons are thought to be the main source of Aβ in the adult brain. Moreover, the ability of neurons to generate cholesterol in the adult brain is impaired during development. However, astrocytes can produce cholesterol and transport it to neurons with apolipoprotein E (apoE)47. ApoE is the major genetic risk factor for sporadic AD. This has led to the hypothesis that apoE regulates Aβ formation via modulation of lipid raft functions48. Recently, astrocyte-derived cholesterol has been shown to regulate Aβ formation in vivo and influence processes involved in inflammation and neurodegeneration49. In our study, we quantified the sum of lipid classes when the astroglioma cell line was exposed to subpathological amounts of oligomeric Aβ42. We still found a similar trend of lipid changes between plasma and cells treated with oligomeric Aβ42. For example, SM, PI, and TG were significantly higher oligomeric Aβ42-treated cells, and some SM, PI, and TG species were upregulated in AD plasma. However, no significant differences were observed between AD and control in plasma and cells for other lipid groups. The results in the cellular lipidome support findings that Aβ42 plays a contributory if not causal role in mediating changes in plasma and cellular lipid profiles in AD.

The lipidome signature as a biomarker of AD

We also examined whether a battery of plasma lipids can be used to discriminate AD patients from controls. All individual lipids, 9 subgroup lipids, and group lipids were used in the GLMnet algorithm. We observed that three classification models, using either TG, ChE, and SM, had significant power in discriminating AD from controls, with >80% AUC. Additionally, individual lipids in TG, ChE, and SM showed even higher AUC than group lipids. Therefore, measurement of these group lipids using mass spectrometry will provide renewed insight in the underlying mechanisms of AD and provide additional drug targets. Taken together, our findings suggest that alterations in both cholesterol and sphingolipid metabolism may play an important role in the pathobiology of AD.

AD genetic risk, lipids, and AD

We examined the relationships between AD PRS and the AD-associated lipids in our sample. Even though no significant association was found after FDR correction, we observed a number of lipid species that were nominally differentially affected between AD and controls, most of which were PC, SM, and TGs. Our data suggest that these lipids might mediate the effect of several SNPs linked to AD.

We also investigated individual AD-related SNPs and lipid levels. Significant associations between AD-related SNPs and individual lipids were only observed before FDR correction. However, we found all SNPs having nominally significant differential association with a certain number of lipid species between AD and control group.

FERMT2 and MS4A6A genes showed a significantly differential association with lipids in all lipid classes across disease groups. FERMT2 is a member of the Fermitin family of proteins, which are involved in cell–matrix adhesion complexes. Shulman et al.50 validated the association of FERMT2 with AD risk after performing a gene screen and in vivo studies in Drosophila melanogaster. Their work showed altered expression of both FERMT2 and CELF1 homologs modulates tau neurotoxicity. It is also upregulated in atherosclerotic plaques, which is a risk factor for AD51. The correlation of FERMT2 with post-stroke brain recovery52 and higher plasma PI in post-stroke mice38 supports the relationship between FERMT2 and PI in our study, i.e. the PI class had the highest proportion of lipids of differential association with FERMT2 between AD and control. It has been hypothesized that FERMT2 regulates APP internalization and degradation53. For instance, FERMT2 silencing induces increased amounts of full-length APP and by-products and FERMT2 over-expression leads to a reduction of APP and its related metabolites. Recently, a direct interaction between FERMT2 and APP—through the F3 domain of FERMT2 and the NxTY motif within APP’s intracellular domain was reported54 and can influence axonal growth55. Importantly, because amyloidogenic processing of APP is dependent on lipid rafts, we postulate that the effect of FERMT2 might be—at least in part—due to alterations in lipid profiles which alter the accumulation of full-length APP or its by-products within the growth cone, impairing vesicle trafficking and/or cell adhesion.

MS4A6A is membrane-spanning 4-domains, subfamily A, member 6A having been revealed to be associated with cortical and hippocampal atrophy independent of glucose metabolism and Aβ deposition56. The important association between MS4A6A and PI (57.14% had differential association with MS4A6A) might indicate the involvement of PI mediating MS4A6A’s effect on brain atrophy. Another gene ABCA7 had an important effect on more than 50% of lipids in the DG lipid class, but with little influence on other lipid classes. DG metabolism and cholesterol synthesis might be the key component linking ABCA7 to Alzheimer’s onset. Increasing evidence has demonstrated that ABCA7 deficiency exacerbates Aβ pathology in vitro and in vivo models. In detail, ABCA7 is involved in the microglial Aβ clearance pathway and accelerated Aβ production57. ABCA7 may also mediate the release of cellular cholesterol and phospholipids to generate HDL. Human ABCA7 mediates the efflux of both cellular cholesterol and phospholipids to apoA-I, whereas mouse ABCA7 mediates only phospholipids but not cholesterol efflux to apoA-I58. Both MS4A6A and ABCA7 have been previously linked to the immune and complement system59, lipid metabolism, and immune system60, immune response and inflammation61, cytokine signaling in immune system 62, cholesterol/lipid metabolism, and immune and complement systems63.

CLU-encoded apoliprotein J associated with the clearance of cellular debris and apoptosis, which was suggested to be involved in Abeta-independent pathways as part of the cascade leading to Alzheimer pathology64. In our study, SM and PE were revealed to be associated with CLU in the pathogenesis of AD. ChE lipids were differentially associated with PICALM, SLC24A4, and SORL1 between AD and control. PICALM has been associated with reduced connectivity of the frontal gyrus with the hippocampus, as well as with the precuneus. The SLC24A4 gene encodes the 24 solute carrier family member 4 protein, which is a member of the K+-dependent Na+/Ca2+ exchanger protein family. These exchanger proteins are widely expressed in brain tissues, suggesting that SLC24A4 may play an important role in the nervous system. The association of this gene with blood pressure in African Americans suggests it may have relevance with AD through vascular disease65. SORL1 belongs to the low-density lipoprotein receptor family, binding ApoE and lipoprotein lipase on membranes66. Decreased Sorl1 has been identified as related to AD67. It is downregulated in lymphoblasts and cortical pyramidal neurons of AD patients. The mechanisms may include APP trafficking and recycling68, Additionally, the association of SORL1 with risk of amnestic mild cognitive impairment (aMCI) has been reported in the Han Chinese69. TG lipids were correlated with BIN, which functions in clathrin-mediated endocytosis and endocytic recycling, as does the AD risk gene PICALM. DNA methylation of the BIN1 promoter has been suggested as a possible epigenetic mechanism influencing AD risk.

Several prior studies have been conducted to explore the potential pathological roles of AD-related SNPs. A review of GWAS-identified risk genes for AD found they were clustered into three main molecular pathways: lipid metabolism, immune function, and endosome vesicle cycling70. The lipids that have shown marked differences between AD versus controls which been directly and indirectly linked to at least one of these mechanisms. The significant associations between lipid profiles and AD which were observed in our study encouraged us to further explore the possible mechanisms of lipids changes in AD patients.

Our results highlight that genetic pathway and SNPs related to AD influence lipids that are associated with AD. These results reinforce the importance of lipid metabolism and dysregulation in AD. It also suggests inflammation, ion channel modification, and Aβ pathways influence lipid levels that are dysregulated in AD. While studies examining the exact mechanisms linking these SNPs with reported lipid changes in AD patients are nascent in the current literature, our results provide renewed insights on potential lipid-related mechanisms in AD which may be examined further in preclinical and clinical studies.

Limitations

Firstly, the sample size was around 40 each in the AD and paired control group, which provides enough power for analyzing 9 lipid classes. However, the strength of the data is limited for examining a large number of individual lipids. FDR correction was used to reduce the bias, although a larger cohort is needed to replicate the findings.

Secondly, we did not subclassify AD to different stages. In addition, we did not look at overlapping cerebral vascular disease in AD patients because only 10 of 40 AD subjects had MRI scanning. Therefore, future studies will look at lipid differences between control, pure AD, and mixed AD in the same stage.

Thirdly, our study is useful for exploring clinical biomarkers of AD because plasma lipids are relatively easy to extract. However, plasma lipids may also be affected by damage to peripheral organs as well, which limits the accuracy of any association between changes in plasma lipid levels and brain pathology. The lipidomics of CSF or post-mortem brain samples from AD patients will be necessary to validate our findings in the future.

Conclusion

Our findings suggest that plasma lipids may differentiate between AD and cognitively normal controls and lipids models can be applied to discriminate the two groups. In addition, AD-related SNPs may have a different association with lipids between AD and controls and the underlying mechanisms need to be explored further in the future. In summary, our study provides evidence that certain lipids may be involved in AD pathogenesis and are associated with AD-related SNPs.

References

  1. Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137–152 (2011).

    PubMed  PubMed Central  Article  Google Scholar 

  2. Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K. & Perry, G. Oxidative stress in Alzheimer’s disease. Biochim. Biophys. Acta 1502, 139–144 (2000).

    CAS  PubMed  Article  Google Scholar 

  3. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358–372 (2015).

    CAS  PubMed  Article  Google Scholar 

  4. Xu, J. et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer’s disease: Snapshot of a pervasive metabolic disorder. Biochim. Biophys. Acta 1862, 1084–1092 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H. & Burns, J. M. Is Alzheimer’s disease a systemic disease? Biochim. Biophys. Acta 1842, 1340–1349 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. Dart, C. Lipid microdomains and the regulation of ion channel function. J. Physiol. 588, 3169–3178 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. Brugger, B. Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry. Annu. Rev. Biochem. 83, 79–98 (2014).

    PubMed  Article  CAS  Google Scholar 

  8. Walter, A. et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25, 1299–1303 (2004).

    CAS  PubMed  Article  Google Scholar 

  9. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20, 415–418 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Casanova, R. et al. Blood metabolite markers of preclinical Alzheimer’s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 12, 815–822 (2016).

    PubMed  PubMed Central  Article  Google Scholar 

  11. Sachdev, P. S. et al. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int.Psychogeriatr. 22, 1248–1264 (2010).

    PubMed  Article  Google Scholar 

  12. Wong, M. W. K. et al. Plasma lipidome variation during the second half of the human lifespan is associated with age and sex but minimally with BMI. PLoS ONE 14, e0214141 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. Dahlgren, K. N. et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046–32053 (2002).

    CAS  PubMed  Article  Google Scholar 

  14. Meng, X. et al. Association between increased levels of amyloid-beta oligomers in plasma and episodic memory loss in Alzheimer’s disease. Alzheimers Res Ther. 11, 89 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  15. Wang, M. J. et al. Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimers Res. Ther. 9, 98 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. Mather, K. A. et al. Investigating the genetics of hippocampal volume in older adults without dementia. PLoS ONE 10, e0116920 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  17. Mather, K. A. et al. Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults. Sci. Rep. 6, 23675 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. Euesden, J., Lewis, C. M. & O’Reilly, P. F. PRSice: Polygenic Risk Score software. Bioinformatics 31, 1466–1468 (2015).

    CAS  PubMed  Article  Google Scholar 

  19. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. Apostolova, L. G. et al. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurol. 75, 328–341 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  21. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).

    PubMed  PubMed Central  Article  Google Scholar 

  22. Team, R. C. R: A language and environment for statistical computing https://www.R-project.org/ (2018).

  23. Kuhn, M . et al. Caret: Classification and Regression Training. R package version. (2018)..

  24. Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).

    Article  Google Scholar 

  25. Podlisny, M. B. et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270, 9564–9570 (1995).

    CAS  PubMed  Article  Google Scholar 

  26. Seubert, P. et al. Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature 359, 325–327 (1992).

    CAS  Article  PubMed  Google Scholar 

  27. Olsen, A. S. B. & Faergeman, N. J. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 7, https://doi.org/10.1098/rsob.170069 (2017).

  28. Mielke, M. M. et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 6, 378–385 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. Mielke, M. M. & Lyketsos, C. G. Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? Neuromol. Med. 12, 331–340 (2010).

    CAS  Article  Google Scholar 

  30. Varma, V. R. et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med. 15, e1002482 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. Han, X. et al. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6, e21643 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. Hussain, G. et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 18, 26 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  33. Li, Z. et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol. Cell. Biol. 31, 4205–4218 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. Whiley, L. et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer’s disease. Neurobiol. Aging 35, 271–278 (2014).

    CAS  PubMed  Article  Google Scholar 

  35. Atri, A. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. Handb. Clin. Neurol. 136, 971–984 (2016).

    PubMed  Article  Google Scholar 

  36. Ojo, J. O. et al. Converging and differential brain phospholipid dysregulation in the pathogenesis of repetitive mild traumatic brain injury and Alzheimer’s disease. Front. Neurosci. 13, 103 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  37. Arancio, O. PIP2: a new key player in Alzheimer’s disease. Cellscience 5, 44–47 (2008).

    PubMed  PubMed Central  Google Scholar 

  38. Sabogal-Guaqueta, A. M., Villamil-Ortiz, J. G., Arias-Londono, J. D. & Cardona-Gomez, G. P. Inverse phosphatidylcholine/phosphatidylinositol levels as peripheral biomarkers and phosphatidylcholine/lysophosphatidylethanolamine-phosphatidylserine as hippocampal indicator of postischemic cognitive impairment in rats. Front. Neurosci. 12, 989 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  39. Gerl, M. J. et al. Cholesterol is inefficiently converted to cholesteryl esters in the blood of cardiovascular disease patients. Sci. Rep. 8, 14764 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. Proitsi, P. et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease. Transl. Psychiatry 5, e494 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. Hejazi, L. et al. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer’s disease brains. Biochem. J. 438, 165–175 (2011).

    CAS  PubMed  Article  Google Scholar 

  42. Wood, P. L. et al. Targeted lipidomics of fontal cortex and plasma diacylglycerols (DAG) in mild cognitive impairment and Alzheimer’s disease: validation of DAG accumulation early in the pathophysiology of Alzheimer’s disease. J. Alzheimer’s Dis. 48, 537–546 (2015).

    CAS  Article  Google Scholar 

  43. Shin, J., Xie, D. & Zhong, X. P. MicroRNA-34a enhances T cell activation by targeting diacylglycerol kinase zeta. PLoS ONE 8, e77983 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. Kalmijn, S. et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese–American elderly men. The Honolulu-Asia aging study. Arterioscler. Thromb. Vasc. Biol. 20, 2255–2260 (2000).

    CAS  PubMed  Article  Google Scholar 

  45. Tajima, Y. et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis. 12, 68 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Ben Haim, L. & Rowitch, D. H. Functional diversity of astrocytes in neural circuit regulation. Nat. Rev. Neurosci. 18, 31–41 (2017).

    CAS  PubMed  Article  Google Scholar 

  47. Jeong, W., Lee, H., Cho, S. & Seo, J. ApoE4-induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer’s disease. Mol. Cells 42, 739–746 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhang, J. & Liu, Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 6, 254–264 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. Oksanen, M. et al. Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cell. Mol. Life Sci. 76, 2739–2760 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. Shulman, J. M. et al. Functional screening in Drosophila identifies Alzheimer’s disease susceptibility genes and implicates Tau-mediated mechanisms. Hum. Mol. Genet. 23, 870–877 (2014).

    CAS  PubMed  Article  Google Scholar 

  51. Oksala, N. et al. Kindlin 3 (FERMT3) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds. Atherosclerosis 242, 145–154 (2015).

    CAS  PubMed  Article  Google Scholar 

  52. Ellison, J. A. et al. Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 29, 1698–1706 (1998). discussion 1707.

    CAS  PubMed  Article  Google Scholar 

  53. Chapuis, J. et al. Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol. 133, 955–966 (2017).

    CAS  PubMed  Article  Google Scholar 

  54. Eysert, F. et al. Alzheimer’s genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner. Mol. Psychiatry https://doi.org/10.1038/s41380-020-00926-w (2020).

  55. Sosa, L. J. et al. Amyloid precursor protein is an autonomous growth cone adhesion molecule engaged in contact guidance. PLoS ONE 8, e64521 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. Ramirez, L. M. et al. Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol. Aging 39, 82–89 (2016).

    CAS  PubMed  Article  Google Scholar 

  57. Aikawa, T., Holm, M. L. & Kanekiyo, T. ABCA7 and pathogenic pathways of Alzheimer’s disease. Brain Sci. 8, https://doi.org/10.3390/brainsci8020027 (2018).

  58. Wang, X. & Paigen, B. Genetics of variation in HDL cholesterol in humans and mice. Circ. Res. 96, 27–42 (2005).

    CAS  PubMed  Article  Google Scholar 

  59. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet. 41, 1094–1099 (2009).

    CAS  PubMed  Article  Google Scholar 

  60. Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49, 1373–1384 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. MahmoudianDehkordi, S. et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease-An emerging role for gut microbiome. Alzheimers Dement. 15, 76–92 (2019).

    PubMed  Article  Google Scholar 

  62. Walker, D. G., Tang, T. M. & Lue, L. F. Studies on colony stimulating factor receptor-1 and ligands colony stimulating factor-1 and interleukin-34 in Alzheimer’s disease brains and human microglia. Front. Aging Neurosci. 9, 244 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  63. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 43, 429–435 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. Slot, R. E. R. et al. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Abeta42, levels in non-demented elderly. Neurobiol. Aging 79, 101–109 (2019).

    CAS  PubMed  Article  Google Scholar 

  65. Adeyemo, A. et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 5, e1000564 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  66. Jacobsen, L. et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J. Biol. Chem. 276, 22788–22796 (2001).

    CAS  PubMed  Article  Google Scholar 

  67. Scherzer, C. R. et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 61, 1200–1205 (2004).

    PubMed  Article  Google Scholar 

  68. Rogaeva, E. et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168–177 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. Gao, X. et al. SORL1 genetic variants modulate risk of amnestic mild cognitive impairment in northern Han Chinese. Int. J. Neurosci. 124, 296–301 (2014).

    CAS  PubMed  Article  Google Scholar 

  70. Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 18, 421–430 (2016).

    PubMed  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nady Braidy.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary table 1. Variants of of AD risk genes included in analysis

41398_2021_1362_MOESM2_ESM.docx

Supplementary table 2. Fold change of original abundance of lipids and difference of lipid residuals between AD and control

Supplementary table 3. Comparison of residuals of group lipids in AD and Control group

Supplementary table 4. Differential association of the AD risk PRS scores with lipids between AD and controls

41398_2021_1362_MOESM5_ESM.docx

Supplementary table 5. Significantly differential association of the AD risk variants and the SNPs with lipids between AD and controls

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Thalamuthu, A., Mather, K.A. et al. Plasma lipidome is dysregulated in Alzheimer’s disease and is associated with disease risk genes. Transl Psychiatry 11, 344 (2021). https://doi.org/10.1038/s41398-021-01362-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41398-021-01362-2

Further reading

Search

Quick links